This is a working overview of lyophilization, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-20. Anything still debated is marked as such rather than presented as settled.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Homogentisic acid (2,5-dihydroxyphenylacetic acid) is a phenolic acid usually found in Arbutus unedo (strawberry-tree) honey. It is also present in the bacterial plant pathogen Xanthomonas campestris pv. phaseoli as well as in the yeast Yarrowia lipolytica where it is associated with the production of brown pigments. It is oxidatively dimerised to form hipposudoric acid, one of the main constituents of the 'blood sweat' of hippopotamuses. It is less commonly known as melanic acid, the name chosen by William Prout.
1993/729) Income Tax (Sub-contractors in the Construction Industry) Regulations 1993 (S.I. 1993/743) Income Tax (Employments) Regulations 1993 (S.I. 1993/744) Health and Safety (Miscellaneous Modifications) Regulations 1993 (S.I. 1993/745) Access to Health Records (Control of Access) Regulations 1993 (S.I. 1993/746) Prevention of Terrorism (Temporary Provisions) Act 1989 (Continuance) Order 1993 (S.I. 1993/747) Combined Probation Areas (Northumbria) Order 1993 (S.I. 1993/748) Combined Probation Areas (Staffordshire) Order 1993 (S.I. 1993/749) Combined Probation Areas (Surrey) Order 1993 (S.I. 1993/750) Medicines Control Agency Trading Fund Order 1993 (S.I. 1993/751) Bingo Duty (Exemptions) Order 1993 (S.I. 1993/752) Finance Act 1989, section 158(1) and (2), (Appointed Days) Order 1993 (S.I. 1993/753) Finance Act 1989, section 178(1), (Appointed Day) Order 1993 (S.I. 1993/754) Income Tax (Indexation) Order 1993 (S.I. 1993/755) Personal Equity Plan (Amendment) Regulations 1993 (S.I. 1993/756) Retirement Benefits Schemes (Indexation of Earnings Cap) Order 1993 (S.I. 1993/757) Taxes (Interest Rate) (Amendment No. 2) Regulations 1993 (S.I. 1993/758) Inheritance Tax (Indexation) Order 1993 (S.I. 1993/759) Capital Gains Tax (Annual Exempt Amount) Order 1993 (S.I. 1993/760) Value Added Tax (Accounting and Records) (Amendment) Regulations 1993 (S.I. 1993/761) Value Added Tax (Cash Accounting) (Amendment) Regulations 1993 (S.I. 1993/762) Value Added Tax (Education) Order 1993 (S.I. 1993/763) Value Added Tax (General) (Amendment) (No. 2) Regulations 1993 (S.I.
A major hurdle to overcome is the long reaction time for complete rotation in these systems, which does not compare to rotation speeds displayed by motor proteins in biological systems. In the fastest system to date, with a fluorene lower half, the half-life of the thermal helix inversion is 0.005 seconds. This compound is synthesized using the Barton-Kellogg reaction. In this molecule the slowest step in its rotation, the thermally induced helix-inversion, is believed to proceed much more quickly because the larger tert-butyl group makes the unstable isomer even less stable than when the methyl group is used. This is because the unstable isomer is more destabilized than the transition state that leads to helix-inversion. The different behaviour of the two molecules is illustrated by the fact that the half-life time for the compound with a methyl group instead of a tert-butyl group is 3.2 minutes. The Feringa principle has been incorporated into a prototype nanocar. The car synthesized has a helicene-derived engine with an oligo (phenylene ethynylene) chassis and four carborane wheels and is expected to be able to move on a solid surface with scanning tunneling microscopy monitoring, although so far this has not been observed. The motor does not perform with fullerene wheels because they quench the photochemistry of the motor moiety. Feringa motors have also been shown to remain operable when chemically attached to solid surfaces. The ability of certain Feringa systems to act as an asymmetric catalyst has also been demonstrated.
Sources: en.wikipedia.org
== External links == Clinical trial number NCT03349060 for "Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-1)" at ClinicalTrials.gov Clinical trial number NCT03575871 for "Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-2)" at ClinicalTrials.gov Clinical trial number NCT03720470 for "Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (JADE Compare)" at ClinicalTrials.gov
Besides being a physical barrier, the sulcular epithelium is able to release antimicrobial peptides which retard the growth of bacteria.This is through the secretion of defensins (β-defensins (hBD-1 and hBD-2)) which are a unique feature of the sulcular epithelium as compared to the junctional epithelium. However if plaque build-up occurs due to the lack of proper oral hygiene practices, bacteria are able to adhere to the sulcular epithelium using their fimbriae. It is discovered that the biofilm adhered to the sulcular epithelium consists of a rich content of glycocalyces, suggesting that these virulence factors allow the survival and colonisation of the periodontal pathogens. The fimbriae then induces the inflammatory response via the release of proinflammatory cytokines, leading to bone resorption. During periodontal disease, the epithelial barrier of the sulcular epithelium becomes discontinuous or ulcerated, compromising the integrity of these junctional complexes. This results in an increase in epithelial permeability and facilitates the passage of bacterial products. This is further promoted through the non-keratinised nature of the epithelium which also acts as a semi-permeable membrane. The transport of harmful bacterial products into the gingiva allows the detection of bacteria action which allows the sulcular epithelium to retaliate through the diffusion of the gingival crevicular fluid (GCF) containing inflammatory cells (neutrophils & small lymphocytes) & inflammatory mediators (IL-8, CXCL8 chemokines) into the sulcus.
== Research == Burnham's research is focused on rapid pathogen identification and antibiotic susceptibility testing to prevent infectious diseases. Burnham edited the Journal of Clinical Microbiology, the Clinical Microbiology Newsletter, Clinics in Laboratory Medicine, and the Manual of Clinical Microbiology. She is the co-editor of the textbook The Dark Art of Blood Cultures, which received praise in the Journal of Clinical Microbiology, where Stephen M. Brecher called the work, "a wonderful historical perspective of the past, present, and future of blood cultures." She has had her work on the topic of diagnostic and clinical microbiology published over two hundred times.
Sources: en.wikipedia.org
== Pace-of-play initiatives == As a part of pace-of-play initiatives implemented in 2015, 20-second pitch clocks entered use at Double-A stadiums in 2015. In 2018, the time was shortened to 15 seconds when no runners are on base. Other significant changes implemented in 2018 included beginning extra innings with a runner on second base and limiting teams to eight mound visits during a nine-inning game. In 2019, the number of mound visits was reduced to seven, and pitchers were required to face a minimum of three consecutive batters, unless the side is retired or the pitcher is injured and unable to continue.
M-phase inducer phosphatase: CDC25A; CDC25B; CDC25C; Dual specificity protein phosphatase: DUSP; DUSP1; DUSP2; DUSP4; DUSP5; DUSP6; DUSP7; DUSP10; DUSP16, aka MKP7; Thiosulfate:glutathione sulfurtransferase: KAT, now known as "TSTD1"; Adenylyltransferase and sulfurtransferase: MOCS3; 3-mercaptopyruvate sulfurtransferase: MPST, also known as "TSTD2" Not an enzyme: TBCK; TSGA14; Ubiquitin carboxyl-terminal hydrolase: USP8; Unknown activity: TSTD3
TabA (P31851), an enzyme related to lysA (diaminopimelate decarboxylase) TabB (P31852), an enzyme related to dapD (THDPA succinyl-CoA succinyltransferase, THDPA-ST) TblA (P31850), an enzyme with no close paralogs (identified as a member of SAMe-dependent methyltransferase superfamily by InterPro) This pathway produces TBL; the enzyme TblF finalize the synthesis by linking TBL to Thr to form tabtoxin.
It's good to be with friends and family as we struggle to deal with this immense loss ... and try to celebrate this immense life. We are looking for all the usual things: comfort, purpose, answers, something to hold on to, a way to let him go in peace. Mostly, we are feeling heartbroken over the death of our beautiful friend. He was a sweet man with a keen sense of humor and a deep sense of humanity. He was an amazing musician, an inspiration, and a comfort to so many. He made great music and gifted it to the world. We are proud to have known him, to be his friend, and to create music with him. For the past decade, Layne struggled greatly—we can only hope that he has at last found some peace. We love you, Layne. Dearly. And we will miss you ... endlessly. In 2010, in an interview on VH1's Celebrity Rehab, former Alice in Chains bass player Mike Starr said that he was the last person to see Staley alive and had spent time with him the day before his death, April 4 (Starr's birthday). Starr claimed that Staley was very sick but would not call 9-1-1. They briefly argued, which ended with Starr storming out. Starr stated that Staley called after him as he left and said: "Not like this, don't leave like this." Starr expressed regret for not calling 9-1-1, and stated that Staley had threatened to sever their friendship if he did. Starr also regretted being high on benzodiazepines that night and having walked out of the door. Staley's mother was insistent that neither she nor anyone in her family blamed Starr for Staley's death, telling Starr: "Layne would forgive you.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.